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Background: Hypertension has been presumed to be correlated with the coronavirus disease 2019 (COVID-19) 
severity. The most common electrolyte disturbance in COVID-19 patients is hyponatremia. It is correlated with 
increased mortality. 
Objective: This research purposed to investigate the correlation between hypertension and hyponatremia in 
COVID-19 patients. 
Methods: A cross-sectional study including hospitalized COVID-19 patients was conducted at Dr. Wahidin Sudiro 
Husodo General Hospital, Mojokerto, Indonesia, from December 2020 to January 2021. We analyzed data about 
the blood pressure and sodium level data of COVID-19 patients. The statistical analysis process was performed 
using IBM SPSS version 23.0.
Results: A total of 98 eligible patients were involved in the analysis. The prevalence of hypertension and hypona-
tremia among COVID-19 patients was 55.1% and 79.6%, respectively. Hyponatremia prevalence was higher in 
hypertensive patients than normotensive patients. Hypertension increased the risk of hyponatremia in COViD-19 
patients (90.7% vs. 65.9%; OR = 5.06; 95% CI = 1.66 - 15.4; p = 0.002). 
Conclusion: This single-center cross-sectional study revealed that, in COVID-19 patients, the presence of 





 A novel coronavirus called Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-Cov-2) was found at the end of 2019 
and rapidly spread globally. This global pandemic is an emergency 
faced by all countries around the world. Research in SARS-Cov-2 
revealed that some variables are correlated with the prognosis of 
COVID-19 patients. The comorbid condition, high d-dimer, older age, 
and multiple organ damage were risk factors for poor outcomes. Hyper-
tension is one of the most frequent comorbidities in coronavirus disease 
2019 (COVID-19) patients.1 The previous study revealed that hyperten-
sion is associated with the COVID-19 severity. That correlation has 
been presumed to be correlated to angiotensin-converting enzyme 2 
(ACE2).2 The spike protein of SARS-Cov-2 attaches to ACE2 and leads 
downregulation or depletion of ACE2.3 
 
 Prior studies demonstrated that patients with COVID-19 tend 
to suffer from electrolytes imbalance, particularly sodium balance 
disorder. It was correlated with greater mortality and severity of 
COVID-19 patients.4,5 The latest study demonstrated an association 
among COVID-19, ACE-2, and renin-angiotensin-aldosterone-system 
(RAS) pathway that contributes to electrolyte disturbance and disease 
severity of COVID-19.4 However, the evidence is limited and still need 
for further investigation with better study design. In developing 
countries such as Indonesia, the study related to this topic is still 
limited. Therefore, this research purposed to investigate the correlation 
between hypertension and hyponatremia in COVID-19 patients.
2. Method
2.1.Study Design
 We completed a single-center cross-sectional research. This 
research had been recognized by the ethical committee and conformed 
with the principles of the Helsinki declaration. From December 1st, 
2020 to January 30th, 2021, we consecutively selected COVID-19 
patients in Dr. Wahidin Sudiro Husodo General Hospital, Mojokerto, 
East Java, Indonesia. We included all COVID-19 confirmed cases 
hospitalized in Dr. Wahidin Sudiro Husodo General Hospital. We 
excluded the patient with incomplete data. The confirmed case was 
defined as patients who had a positive result of real-time fluorescent 
reverse transcription-polymerase chain reaction (RT-PCR). All import-
ant information about the patients was collected from the medical 
record. Hypertension was the documented systolic blood pressure of ≥
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the patients had a blood sodium level less than 135 mmHg.7 
2.2. Statistical analysis
All statistical analysis process was conducted using SPSS 23.0 (IBM) 
software. The baseline characteristic of the patients was showed in the 
table. The number and percentage were used to describe the categori-
cal data. For continuous data, the mean and standard deviation (SD) 
were used to show the continuous data with normal distribution. We 
showed the data using the median and interquartile range (IQR) for the 
continuous data without normal distribution. The comparison between 
2 continuous variables was assessed using Mann Whitney test for 
abnormally distributed data and the independent t-test for normally 
distributed data. The comparison between the two categorical variables 
was tested using the Fisher's exact test or the Chi-squared test. An odds 
ratio (OR) was calculated to measure a correlation between hyperten-
sion and hyponatremia in COVID-19 patients. The statistically signifi-
cant was considered if p-value <0.05.
3. Results
 A total of 116 COVID-19 patients were identified from our 
registry system. Of those, a total of 18 patients were excluded because 
of incomplete data. Finally, a total of 98 COVID-19 confirmed cases 
were involved in the data analysis. Patients were groupped into 
hypertension group (n = 54) and no hypertension group (n = 44) 
(Figure 1). The prevalence of hypertension among COVID-19 patients 
was 55.1%. The mean age in the hypertension group and no hyperten-
sion group was 56.3 ± 11.3 and 54.8 ± 13.6 years old, respectively. 
Overall, we did not find the significant differences in age, gender, and 
the prevalence of comorbid conditions such as chronic kidney disease, 
diabetes mellitus, heart failure, or coronary artery disease in both 
groups. Baseline characteristics information of the included patients 
are summarized in Table 1.
prevalence of hyponatremia was greater in the hypertension group than 
no hypertension group patients. It was related to a higher risk of 
hyponatremia, about 5.06-fold.
 Several previous studies have discussed hypertension, 
hyponatremia in COVID-19 patients. A pooled analysis study about 
hypertension in patients with COVID-19 by Lippi et al. suggested that 
 The prevalence of hyponatremia among COVID-19 all 
patients was 79.6%. The prevalence of hyponatremia was greater in the 
hypertension group than no hypertension group patients. From the 
Chi-square test, it pointed out that hypertension increased the risk of 
hyponatremia in COViD-19 patients (90.7% vs. 65.9%; OR = 5.06; 
95% CI = 1.66 - 15.4; p = 0.002) (Figure 2). The mortality rates in 
COVID-19 patients suffered from hypertension were 57.4 %, whereas 
the mortality rates in COVID-19 patients without pressure were 54.5 %, 
respectively (OR 1.36; 95% CI = 0.51 - 3.65; p = 0.17)
4. Discussion
 Our current study confirmed that hypertension was associat-
ed with hyponatremia in covid 19 patients COVID-19 patients. The 
high blood pressure may be correlated with an up to 2.5-fold higher risk 
of fatal or severe COVID-19. It was also confirmed from a pooled 
analysis that COVID-19 severity is correlated with lower serum concen-
trations of potassium, calcium, and sodium.8 Another study by Huang 
et al. reported that hypertensive patients tend to show higher severity 
and mortality, from OR of hypertension were 1.562 (95% CI: 0.929 - 
2.625; P=0.092) and 1.262 (95% CI: 0.683 - 2.332; P=0.458).9  
22
Figure 1. Study flowchart of patients’ selection.
Table 1. Baseline characteristics of the patients.
COVID-19 patients were registered from December 1st 2020 to january, 30th 2021
(n=116)









(n = 54) 
No 
Hypertension 
(n = 44) 
P-value 
Male sex 26 (48.2) 24 (54.5) 0.529 
Age, years old 56.3 + 11.3 54.8 + 13.6 0.356 
Comorbid disease 
Coronary artery 
disease 26 (48.1) 17 (38.6) 0.345 
Diabetes mellitus 1 (1.85) 1 (2.2) 0.883 
Heart failure 25 (46.2) 21 (47.7) 0.888 
Chronic kidney 
disease 4 (7.4) 5 (11.3) 0.500 
Blood Pressure 
SBP, mmHg 170 (90 - 250) 112.5 (90 - 135) 0.398 
DBP, mmHg 103 (36 - 170) 77.5 (70 - 85) 0.624 
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Figure 2. Prevalence of hyponatremia in hypertension group and no 
hypertension group.
SARS-Cov-2 infected the human body, RAS activation was altered by 
downregulated ACE-2. During SARS-CoV-2 virus entrance and replica-
tion, ACE-2 is depleted and downregulated.16 This leads loss of the 
antagonist function of ACE-2 against the classical RAS pathway. This 
situation leads the RAS equilibrium towards the ACE/Angiotensin II 
pathway. As a result, Angiotensin II will activate the AT2 receptors that 
impact vasodilatation and cause an increased natriuresis.17 The 
natriuresis cause depletion of sodium levels that leads to hyponatre-
mia.18 Hyponatremia is also the most frequent electrolyte imbalance in 
COVID-19 patients. It is caused by inappropriate antidiuretic hormone 
secretion. SIADH probably a result of the marked elevation of inflam-
matory cytokines, especially interleukin-6.5
 Our study has several drawbacks. First, it was a single-center 
cross-sectional study. Second, the sample size was small. However, this 
study provided preliminary data about the correlation between 
hypertension and hyponatremia in hospitalized COVID-19 patients.
5. Conclusion
 Based on this single-center cross-sectional study, we revealed 
hypertension was correlated with a higher risk of hyponatremia in 
COVID-19 patients. We suggested further multi-center study with a 
better design larger size of study participants.
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